BR0309576A - Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável - Google Patents

Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável

Info

Publication number
BR0309576A
BR0309576A BR0309576-2A BR0309576A BR0309576A BR 0309576 A BR0309576 A BR 0309576A BR 0309576 A BR0309576 A BR 0309576A BR 0309576 A BR0309576 A BR 0309576A
Authority
BR
Brazil
Prior art keywords
variant
fviia
fvii
mammal
disorder
Prior art date
Application number
BR0309576-2A
Other languages
English (en)
Inventor
Jesper Mortensen Haaning
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of BR0309576A publication Critical patent/BR0309576A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

"VARIANTE DE POLIPEPTìDEO DO FATOR VII (FVII) OU FATOR VIIA (FVIIA), SEQUêNCIA DE NUCLEOTìDEO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA, USO DE UMA VARIANTE E MéTODO PARA TRATAR UM MAMìFERO QUE TENHA UMA DOENçA OU UM DISTúRBIO EM QUE A FORMAçãO DE COáGULO é DESEJáVEL". A presente invenção diz respeito a novas variantes polipetídicas de polipeptídeos do fator VII (FVII) ou fator VIIa (FVIIa), onde as ditas variantes compreendem uma substituição de aminoácido nas posições 10 e 32 e onde as ditas variantes ainda compreendem uma porção de açúcar covalentemente ligada a um sítio de N-glicosilação introduzido in vivo localizado fora do dominio Gla. Tais variantes de polipeptídeo são úteis em terapia, em particular para o tratamento de uma variedade de distúrbios relacionados com a coagulação, tais como trauma.
BR0309576-2A 2002-04-30 2003-04-29 Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável BR0309576A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37667902P 2002-04-30 2002-04-30
PCT/DK2003/000276 WO2003093465A1 (en) 2002-04-30 2003-04-29 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Publications (1)

Publication Number Publication Date
BR0309576A true BR0309576A (pt) 2005-02-09

Family

ID=29401388

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309576-2A BR0309576A (pt) 2002-04-30 2003-04-29 Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável

Country Status (22)

Country Link
US (6) US7700733B2 (pt)
EP (1) EP1499719B1 (pt)
JP (2) JP2005523723A (pt)
KR (1) KR101121593B1 (pt)
CN (2) CN1665925A (pt)
AT (1) ATE488581T1 (pt)
AU (2) AU2003221469A1 (pt)
BR (1) BR0309576A (pt)
CA (1) CA2483478A1 (pt)
CY (1) CY1111626T1 (pt)
DE (1) DE60334983D1 (pt)
DK (1) DK1499719T3 (pt)
ES (1) ES2355713T3 (pt)
IL (1) IL164764A (pt)
MX (1) MXPA04010781A (pt)
NZ (1) NZ536340A (pt)
PL (1) PL373728A1 (pt)
PT (1) PT1499719E (pt)
RU (1) RU2004134726A (pt)
SI (1) SI1499719T1 (pt)
WO (1) WO2003093465A1 (pt)
ZA (1) ZA200409475B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
DK1499719T3 (da) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
AU2003266931B2 (en) * 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
AU2004247799B2 (en) * 2003-06-19 2009-12-03 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
EP3594222B1 (en) 2003-12-01 2022-08-03 Novo Nordisk Health Care AG Virus filtration of liquid factor vii compositions
MXPA06006886A (es) 2003-12-19 2006-09-04 Novo Nordisk Healthcare Ag Composiciones estabilizadas de polipeptidos del factor vii.
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
BRPI0515163A (pt) * 2004-09-10 2008-07-08 Pharmaorigin Aps métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local
JP2008525381A (ja) 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ES2397851T3 (es) 2005-07-13 2013-03-11 Novo Nordisk Health Care Ag Células de inactivación proteínica de la célula huésped para la producción de proteínas terapéuticas
EP1924689B1 (en) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Hydrophobic interaction chromatography purification of factor vii polypeptides
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
WO2007124127A2 (en) * 2006-04-21 2007-11-01 Wake Forest University Health Sciences Structurally modified acellular tissue engineering scaffolds and methods of production
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
EP2114379A2 (en) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Factor vii and viia compositions
SI2147096T1 (sl) 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
AU2010290077C1 (en) 2009-08-24 2015-12-03 Bioverativ Therapeutics Inc. Coagulation factor IX compositions and methods of making and using same
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
CN107412749A (zh) * 2010-02-22 2017-12-01 优势医疗公司 治疗脑的出血性病状的方法和组合物
RU2606169C2 (ru) 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2554161A1 (en) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
WO2013122617A1 (en) 2012-02-15 2013-08-22 Amunix Operating Inc. Factor viii compositions and methods of making and using same
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
PL2938351T3 (pl) 2012-12-24 2020-03-31 Coagulant Therapeutics Corporation Krótko działające polipeptydy czynnika VII
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
PT87688B (pt) 1987-06-12 1992-09-30 Hoechst Japan Processo para a preparacao de proteina hibrida c
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ATE300519T1 (de) 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
HUT63459A (en) 1990-01-26 1993-08-30 Immuno Ag Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process
AU651573B2 (en) 1990-01-29 1994-07-28 Novo Nordisk Health Care Ag Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
WO1992009698A1 (en) 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
WO1994027631A1 (en) 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
CA2103546C (en) 1991-02-28 2002-10-01 Kathleen L. Berkner Modified factor vii
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
JPH0720127A (ja) 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69735597T2 (de) 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE390441T1 (de) 1998-10-30 2008-04-15 Novozymes As Niedrigallergene proteinvarianten
CN1325443A (zh) 1998-10-30 2001-12-05 诺沃奇梅兹有限公司 具有减弱的变应原性的糖基化蛋白
WO2000028065A1 (en) 1998-11-06 2000-05-18 Novo Nordisk A/S Method for the production of fvii
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU2001287550B2 (en) * 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
CA2420892A1 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7024693B2 (en) * 2001-11-13 2006-04-04 Sun Microsystems, Inc. Filter-based attribute value access control
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
DK1499719T3 (da) 2002-04-30 2011-02-28 Bayer Healthcare Llc Faktor VII- eller VIIa-polypeptidvarianter
AU2003266931B2 (en) 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
AU2004247799B2 (en) 2003-06-19 2009-12-03 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
US7185570B2 (en) 2005-01-18 2007-03-06 Chih-Ching Hsieh Spanner with enhancing structure for positioning electronic devices installed therein
US20060252669A1 (en) 2005-05-06 2006-11-09 Marija Heibel Fabric care composition comprising polymer encapsulated fabric or skin beneficiating ingredient

Also Published As

Publication number Publication date
US7700733B2 (en) 2010-04-20
DK1499719T3 (da) 2011-02-28
KR20040106424A (ko) 2004-12-17
US20060270001A1 (en) 2006-11-30
CN101942019A (zh) 2011-01-12
US9353365B2 (en) 2016-05-31
US20060276377A1 (en) 2006-12-07
US20060270002A1 (en) 2006-11-30
NZ536340A (en) 2006-09-29
EP1499719A1 (en) 2005-01-26
EP1499719B1 (en) 2010-11-17
AU2003221469A1 (en) 2003-11-17
IL164764A0 (en) 2005-12-18
ES2355713T3 (es) 2011-03-30
DE60334983D1 (de) 2010-12-30
PL373728A1 (en) 2005-09-05
KR101121593B1 (ko) 2012-04-12
PT1499719E (pt) 2011-02-09
CY1111626T1 (el) 2015-10-07
ATE488581T1 (de) 2010-12-15
AU2008261165A1 (en) 2009-01-15
CN1665925A (zh) 2005-09-07
SI1499719T1 (sl) 2011-03-31
MXPA04010781A (es) 2005-03-07
JP2005523723A (ja) 2005-08-11
US20060111282A1 (en) 2006-05-25
JP2010213706A (ja) 2010-09-30
US20100260741A1 (en) 2010-10-14
WO2003093465A1 (en) 2003-11-13
IL164764A (en) 2013-07-31
RU2004134726A (ru) 2005-06-10
US20060270000A1 (en) 2006-11-30
CA2483478A1 (en) 2003-11-13
ZA200409475B (en) 2005-09-28

Similar Documents

Publication Publication Date Title
BR0309576A (pt) Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
BRPI0411650A (pt) variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
Silva-Filho et al. The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions
US8563507B2 (en) Method of treating a disease or condition characterized by aberrant epithelial cell proliferation
ES2284828T3 (es) Propeptidos de gdf modificados y estabilizados y usos de los mismos.
BR0212586A (pt) Composição, uso de uma combinação de ipratrópio ou um sal deste e de xilometazolina ou um sal desta, e, métodos para o tratamento de uma condição selecionada ao grupo que consiste de sintomas associados com o resfriado comum e sintomas associaods com a rinite e para estabilizar uma solução aquosa de ipratrópio ou um sal deste e xilometazolina ou um sal desta
BR0215212A (pt) Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
Rajah et al. 7S nerve growth factor is an insulin-like growth factor-binding protein protease
BRPI0720282B8 (pt) construção proteica, composição farmacêutica, e, kit
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
PT861261E (pt) Sequências nucleotídicas e proteicas de genes delta de vertebrado e métodos nelas baseados
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
TR200101539T2 (tr) Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri.
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
Leveugle et al. Heparin promotes ß-secretase cleavage of the Alzheimer's amyloid precursor protein
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
BR0204494A (pt) Composto, composição, sistema de reativos, utilização de um composto, processo de preparação do mesmo, e, método de medida do tempo de tromboplastina parcialmente ativada
DE60222669D1 (de) Asthma-assoziiertes gen
BR0116151A (pt) Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica
ATE554393T1 (de) Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen
Seiffert et al. Vitronectin modulates glycosaminoglycan dependent reactions of protein C inhibitor
BR0209934A (pt) Composto, utilização de um composto, processo de seleção de um composto, e composição farmacêutica.
WO2003020897A3 (en) Compositions and methods relating to ovary specific genes and proteins

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]